Author/Editor		Cukjati, Marko; Domanovič, Dragoslav
Title		Vključevanje bolnikov z dedno hemokromatozo med krvodajalce
Translated title		Recruitment of patients with hereditary haemochromatosis as blood donors
Type		članek
Source		Zdrav Vestn
Vol. and No.		Letnik 73, št. Suppl 1
Publication year		2004
Volume		str. I-77-80
Language		slo
Abstract		Background. Hereditary haemochromatosis is the most common inherited disorder in white persons with prevalence of about 1 in 200. Therapeutic phlebotomy is an effective treatment for the disease and prevents its sequele. In addition to their altruism, patients with hereditary haemochromatosis have also medical and monetary incentives for blood donation. Current guidelines do not allow haemochromatosis patients to donate blood. About two thirds of patients are eligible as blood donors and about two thirds of therapeutically drawn blood is suitable for transfusion. Therapeutically drawn blood could increase the blood supply by 1.5 to 30%. Conclusions. The number of states that already accept patients with hereditary haemochromatosis as blood donors is increasang. To avoid monetary incentives they offer free phlebotomies for all patients with hereditary haemochromatosis. There have been no reports about higher incidence of transfusion reactions. In Slovenia the number of therapeutic phlebotomy is increasing. We should evaluate the possibilities for recruitment of haemochromatosis patients as blood donors also in our country. It is necessary to modify regulatory restrictions and to ensure that there is no other incentives than altruism for blood donation.
Summary		Izhodišča. Dedna hemokromatoza je najpogostejša dedna bolezen pri belcih s prevalenco okoli 1 na 200. Terapevtski odvzemi krvi so učinkovit način zdravljenja bolezni in preprečevanja njenih zapletov. Bolniki z dedno hemokromatozo imajo poleg altruizma tudi druge motive za dajanje krvi, kot je posredna ali neposredna materialna korist in korist za lastno zdravje. Po veljavnih strokovnih normativih zato ne morejo biti krvodajalci. Okoli dve tretjini bolnikov izpolnjujeta vsa zdravstvena merila za krvodajalce in okoli dve tretjini terapevtsko odvzete krvi izpolnjujeta vse zahteve kakovosti. Z uporabo terapevtsko odvzete krvi za transfuzijo bi po ocenah lahko pokrili od 1,5 do 30% vseh potreb po krvi. Zaključki. Število držav, ki že uvrščajo bolnike z dedno hemokromatozo med krvodajalce, se povečuje. Materialno korist dajanja krvi so izničili z uvedbo brezplačnih odvzemov krvi za vse bolnike z dedno hemokromatozo. Do sedaj ni poročil o večji pogostnosti neželenih učinkov po transfuziji takšne krvi. V Sloveniji število terapevtskih odvzemov krvi pri bolnikih z dedno hemokromatozo v zadnjih letih narašča. Smiselno bi bilo proučiti možnost vključevanja teh bolnikov med krvodajalce tudi pri nas. Ob tem bi bilo potrebno ustrezno spremeniti strokovne normative in zagotoviti pogoje, v katerih bo altruizem edini motiv za dajanje krvi.
Descriptors		HEMOCHROMATOSIS PHLEBOTOMY BLOOD DONORS SAFETY